Patents by Inventor Colin Correnti
Colin Correnti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364183Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: March 2, 2023Publication date: November 16, 2023Inventors: James OLSON, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
-
Publication number: 20230235091Abstract: The present disclosure provides antibodies and polypeptides that specifically bind to mesothelin (MSLN), including bispecific antibodies that bind both MSLN and a T cell antigen (e.g., CD3). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: February 2, 2023Publication date: July 27, 2023Inventors: Colin CORRENTI, Christopher Mehlin, David Meininger, Ashok Bandaranayake
-
Patent number: 11648290Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: GrantFiled: June 21, 2021Date of Patent: May 16, 2023Assignees: FRED HUTCHINSON CANCER CENTER, BLAZE BIOSCIENCE, INC.Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
-
Publication number: 20220016202Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: June 21, 2021Publication date: January 20, 2022Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
-
Publication number: 20210309755Abstract: Mesothelin (MSLN) is expressed on pancreatic cancers, ovarian cancers and mesotheliomas. The present disclosure provides antigen-binding molecules, including anti-MSLN antibodies, and bispecific antigen-binding molecules that bind to both MSLN and a T cell antigen (e.g., CD3) and activate T cells in the presence of MSLN-expressing tumor cells. The antigen-binding molecules of this disclosure are useful for the treatment of diseases and disorders in which a MSLN-targeted immune response is desired and/or therapeutically beneficial. For example, the antigen-binding molecules of the present disclosure are useful for the treatment of various cancers, including pancreatic cancer, ovarian cancer and mesotheliomas.Type: ApplicationFiled: April 6, 2021Publication date: October 7, 2021Inventors: Colin CORRENTI, Ashok BANDARANAYAKE, Christopher MEHLIN, James M. OLSON, Soheil MESHINCHI
-
Patent number: 11090358Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: GrantFiled: September 9, 2016Date of Patent: August 17, 2021Assignees: FRED HUTCHINSON CANCER RESEARCH CENTER, BLAZE BIOSCIENCE, INC.Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
-
Patent number: 10987417Abstract: Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.Type: GrantFiled: June 3, 2019Date of Patent: April 27, 2021Assignee: Fred Hutchinson Cancer Research CenterInventors: Roland K. Strong, Colin Correnti, Leonidas Stamatatos, Andrew McGuire
-
Publication number: 20200188528Abstract: Peptide-antibody complexes, including fusions and conjugates, that target or accumulate in target cells, such as tumors and diseased cells, or enhance the immune system are disclosed. In some embodiments, such complexes function as platforms for attaching and targeting one or more therapeutic agents or detectable agents, including radioisotopes, detectable labels, and/or cytotoxic agents, to target cells in the central nervous system or across the blood brain barrier, cancerous cells, or target cells recognized by the antibody in such complexes. In some complexes, the peptide serves as the targeting mechanism, while other embodiments contemplate the antibody as the targeting mechanism. Peptides and/or antibodies can be engineered to deliver various effector functions in various embodiments. Peptide-antibody complexes that function as immunotherapies and enhance a body's immune system in detecting and/or destroying diseased cells or pathogens are also disclosed.Type: ApplicationFiled: December 19, 2017Publication date: June 18, 2020Inventors: James OLSON, Andrew J. MHYRE, Colin CORRENTI
-
Publication number: 20190375786Abstract: Peptides that are stable to denaturation and degradation by reducing agents, proteases, temperature, and low pH environments are disclosed. Pharmaceutical compositions and uses for peptides, peptide-active agent conjugates, and peptide-detectable agent conjugates comprising such peptides are also disclosed. Peptide compositions, peptide conjugate compositions, and pharmaceutical compositions can be formulated for various routes of delivery, such as oral delivery, and for deliver to various compartments of the body. Peptides of this disclosure are stable and display enhanced pharmacokinetics after such delivery.Type: ApplicationFiled: September 9, 2017Publication date: December 12, 2019Inventors: Emily June GIRARD, Colin CORRENTI, James OLSON, Natalie Winblade NAIRN, Mesfin Mulugeta GEWE, Christopher MEHLIN, Zachary CROOK, Roland STRONG, Scott Ronald PRESNELL
-
Publication number: 20190321461Abstract: Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.Type: ApplicationFiled: June 3, 2019Publication date: October 24, 2019Applicant: Fred Hutchinson Cancer Research CenterInventors: Roland K. Strong, Colin Correnti, Leonidas Stamatatos, Andrew McGuire
-
Publication number: 20190292243Abstract: Peptides that home, migrate to, distribute to, accumulate in, are directed to, and/or bind to tumors, cancerous tissues and cells thereof are disclosed. Pharmaceutical compositions and uses for peptides, peptide-active agent complexes comprising such peptides, or peptide-detectable agent complexes comprising such peptides are additionally disclosed. Such compositions can be formulated for targeted or untargeted delivery of a drug to a target region, tissue, structure or cell. Targeted compositions of the disclosure can deliver peptide, peptide-active agent complexes, or peptide-detectable agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: August 22, 2017Publication date: September 26, 2019Inventors: James OLSON, Theo SOTTERO, Emily GIRARD, Andrew MHYRE, Colin CORRENTI, Christopher MEHLIN, Mesfin Mulugeta GEWE, Gene Gregory HOPPING
-
Publication number: 20190233534Abstract: Groups of bi-specific binding domain constructs (BS-BDC) to treat cancer are described. Each BS-BDC in a group targets a cancer antigen epitope and an immune cell activating epitope that is different from the cancer antigen epitope and immune cell activating epitope targeted by another BS-BDC in the group. The different cancer antigen epitopes can be on the same cancer antigen.Type: ApplicationFiled: July 14, 2017Publication date: August 1, 2019Applicant: Fred Hutchinson Cancer Research CenterInventors: Christopher Mehlin, Colin Correnti, James Olson, Roland B. Walter, Ashok Bandaranayake, George S. Laszlo
-
Patent number: 10342863Abstract: Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp 120) and can used as an HIV vaccine.Type: GrantFiled: March 24, 2016Date of Patent: July 9, 2019Assignee: Fred Hutchinson Cancer Research CenterInventors: Roland K. Strong, Colin Correnti, Leonidas Stamatatos, Andrew McGuire
-
Publication number: 20190117728Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in amd/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: September 9, 2016Publication date: April 25, 2019Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
-
Publication number: 20190101528Abstract: Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.Type: ApplicationFiled: December 11, 2018Publication date: April 4, 2019Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventors: James Olson, Christopher Mehlin, Colin Correnti, Roland K. Strong
-
Publication number: 20180371033Abstract: Peptides that home, distribute to, target, are directed to, or accumulate in tumors, cancers, or diseased cells are disclosed. Peptides that cross the blood brain barrier and home, distribute to, target, are directed to, or accumulate in the brain and in a specific region of the brain are also disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are additionally disclosed. Such compositions can be formulated for targeted or untargeted delivery of a drug to a target region, tissue, structure or cell. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: June 24, 2016Publication date: December 27, 2018Applicant: Fred Hutchinson Cancer Research CenterInventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Andrew James Mhyre, Mi-Youn Brusniak, Theo Sottero
-
Patent number: 10156559Abstract: Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.Type: GrantFiled: December 10, 2013Date of Patent: December 18, 2018Assignee: Fred Hutchinson Cancer Research CenterInventors: James Olson, Christopher Mehlin, Colin Correnti, Roland Strong
-
Publication number: 20180117140Abstract: Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.Type: ApplicationFiled: March 24, 2016Publication date: May 3, 2018Inventors: Roland K. STRONG, Colin CORRENTI, Leonidas STAMATATOS, Andrew McGUIRE
-
Publication number: 20150322123Abstract: Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.Type: ApplicationFiled: December 10, 2013Publication date: November 12, 2015Inventors: James OLSON, Christopher MEHLIN, Colin CORRENTI, Roland STRONG
-
Publication number: 20150316536Abstract: Methods and systems for discovering drug candidates are disclosed. Methods and systems can include generating libraries of potential drug candidates (e.g., libraries of peptides) that can be screened to identify sub-libraries of potential drug candidates (e.g., sub-libraries of peptides) having selected pharmacological properties. Methods of making and using peptide libraries are also provided. D-amino acid chlorotoxins and D-amino acid chlorotoxin variants are also provided.Type: ApplicationFiled: December 10, 2013Publication date: November 5, 2015Inventors: James OLSON, Christopher MEHLIN, Mark STROUD, Julian SIMON, Colin CORRENTI, Patrick PADDISON, Roland STRONG, Damon MAY